What is Diamedix?
Diamedix operates within the autoimmune diagnostics market, building upon the legacy of ImmunoVision, which has been a leader in supplying reagents for autoimmune research since 1985. The company offers a comprehensive portfolio of products, including purified antigens, monoclonal and polyclonal antibodies, and disease state plasma. Complementing its product offerings, Diamedix provides specialized services such as microtiter plate coating, custom purification, and assay development. These capabilities cater to a diverse clientele, including biotechnology firms, pharmaceutical companies, and contract research organizations. As an integral part of the Calbiotech family, Diamedix is dedicated to advancing global research through its extensive distribution network.
How much funding has Diamedix raised?
Diamedix has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Diamedix
PPP
Public-Private Partnership
What's next for Diamedix?
The substantial late-stage funding secured by Diamedix signals a strong investor confidence in the company's established market presence and future potential. This capital infusion is expected to fuel further expansion of its product lines, enhance its service capabilities, and potentially drive innovation in autoimmune diagnostics. The strategic investment suggests a focus on scaling operations and solidifying its competitive edge, positioning Diamedix for continued leadership in supporting critical research endeavors worldwide.
See full Diamedix company page
